Home Newsfeeds Galmed Reports Results From The Open-label Part Of The ARMOR Study

Galmed Reports Results From The Open-label Part Of The ARMOR Study

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in

byBenzinga Newsdesk

January 4, 2023

1 minute read

Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according to NASH CRN, in 61% of subjects by ranked assessment with a highly statistically significant (p<0.0001) reduction in fibrosis score demonstrated using AI-assisted, digital pathology reading
Highly statistically significant (p<0.0001) reduction in liver stiffness by Fibroscan
Highly statistically significant (p<0.0001) reduction in biochemical markers of liver injury ALT and AST
Highly statistically significant reductions in major fibrosis biomarkers: FIB-4 (p<0.0001), Pro-C3 (p<0.0001) and ELF (p= 0.0038) at week 24
Galmed is submitting all data to the FDA to initiate discussions on incorporating more sensitive histology reading methodologies as primary endpoints in NASH clinical studies and is actively looking for partnering opportunities to continue Aramchol’s clinical development.

ZimVie Announces The Recent Launch Of Biotivity A/C Plus Membrane

By Benzinga Newsdesk

October 10, 8:36 AM

ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental and spine markets, today announced the recent launch of the Biotivity™ A/C Plus Membrane, a growth factor rich membrane used for site coverage

ZIMV

Eco Wave Power Signed A Contract With A Major Energy Company For A Demonstration To Harness Energy From The Waves At The Port Of Los Angeles; No Financial Terms Disclosed

By Benzinga Newsdesk

April 11, 9:15 AM

Eco Wave Power and Major Energy Company will Develop First-Ever US Wave Energy Pilot Station at AltaSea's Premises in the Port of LALOS ANGELES, April 11, 2024 /PRNewswire/ -- Eco Wave Power Global AB (publ)

WAVE

FOXO Technologies On Track To Commence Commercial Rollout Of VITHAR AI Health Coach In Early 2024; Reports Anticipated Reduction In Losses In Excess Of $10M For Q3 2023 Compared To The Prior Quarter

By Benzinga Newsdesk

December 1, 10:08 AM

Reports anticipated reduction in losses in excess of $10 million for the third quarter of 2023 compared to the prior quarterFOXO Technologies Inc. (NYSE:FOXO) ("FOXO" or the "Company"), a leader in the field of

FOXO